Non-lipid-lowering effects of statins on atherosclerosis

Current Cardiology Reports

Volumn 1, Issue 3, 1999, Pages 225-232

  Rosenson, Robert S ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTERIOSCLEROSIS; BLOOD CLOTTING; DRUG EFFECT; HUMAN; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; BLOOD COAGULATION; CYTOKINES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LOVASTATIN; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 0033187330     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0027-7     Document Type: Article

References (70)

1. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279:1643-1650.
2. West of Scotland Coronary Prevention Study Group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440-1445.
3. Freedman DS, Otvos JD, Jeyarajah EJ, et al.: Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998, 18:1046-1053.
4. Rosenson R, Lowe GDO: Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998, 140:271-280.
5. Rosenson RS, Otvos JD, Shalaurova I: Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I Trial. Circulation 1998, 98:I-534.
6. Koudy-Williams J, Sukhova GK, Herrington DM, et al.: Pravastatin has cholesterol lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998, 31:684-691.
7. Ross R: Atherosclerosis an inflammatory disease. N Eng J Med 1999, 340:115-126.
8. Egashira K, Hirooka Y, Kai H, et al.: Reduction in serum cholesterol with pravastatin improves endothelium dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519-2524.
9. Treasure CB, Klein JL, Weintraub WS, et al.: Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995, 332:481-487.
10. Anderson TJ, Meredith IT, Yeung AC, et al.: The effect of cholesterol lowering and antioxidant therapy on endothelium dependent coronary vasomotion. N Engl J Med 1995, 332:488-493.
11. Aengevaeren WRM, Uijen GJH, Jukema JW, et al.: Functional evaluation of lipid lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study. Circulation 1997, 96:429-435.
12. Eichstadt HW, Eskotter H, Hoffmann I, et al.: Improvement of myocardial perfusion by short term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995, 76:122A-125A.
13. van Boven AJ, Jukema JW, Zwinderman AH, et al.: Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996, 94:1503-1505.
14. Andrews TC, Raby K, Barry J, et al.: Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997, 95:324-328.
15. Dangas GZ, Badimon JJ, Smith DA, et al.: Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999, 33: 1294-1304.
16. Winniford M, Hodgson J, Yeung A, et al.: CARAT Study: the effect of cholesterol lowering on coronary blood flow. 66th Congress of the European Atherosclerosis Society, Florence, Italy, July 1996.
17. Kaesemeyer WH, Caldwell RB, Huang J, et al: Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol lowering actions. J Am Coll Cardiol 1999, 33:234-241.
18. John S, Schlaich M, Langenfeld M, et al: Increased bioavailability of nitric oxide after lipid lowering therapy in hypercholesterolemic patients. A randomized, placebo controlled, double blind study. Circulation 1998, 98:211-216.
19. Laufs U, La Fata V, Plutzky J, et al.: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
20. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al: Effects of the 3 hydroxy 3 methylglutaryl CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin 1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998, 101:2711-2719.
21. Shiomi M, Ito T, Tsukada T, et al.: Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995, 15:1938-1944.
22. Cybulsky MI, Gimbrone MA Jr.: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 25:788-791.
23. Adams DH, Shaw S: Leukocyte endothelial interactions and regulation of leukocyte mitigation. Lancet 1994, 343:831-836.
24. Meerschaert J, Furie MB: The adhesion molecules used by monocyte migration across endothelium include CD11a/ CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium. J Immunol 1995, 154:4099-4112.
25. Weber C, Erl W, Weber KSC, et al.: HMG CoA reductase inhibitors decrease CD11b expression and CD11b dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997, 30:1212-1217.
26. Ridker PM, Hennekens CH, Roitman-Johnson B, et al.: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351:88-92.
27. Hwang SJ, Ballantyne CM, Sharrett AR, et al.: Circulating adhesion molecules VCAM-1, ICAM-1, and E selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997, 96:4210-4225
28. Koh KK, Cardillo C, Bui MN, et al.: Vascular effects of estrogen and cholesterol lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999, 99:354-360.
29. Libby P, Sukhova G, Lee RT, et al.: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995, 25 (Suppl. 2):S9-S12.
30. Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1998, 353:983-984.
31. Kiener PA, Davis PM, Murray JL, et al.: Characterization of the differences in the pro inflammatory effects of HMG CoA reductase inhibitors. European Atherosclerosis Society, 70th EAS Congress, Geneva, Switzerland, September 6-9, 1988. Abstract.
32. Bustos C, Hernandez-Presa MA, Ortego M, et al.: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998, 32:2057-2064.
33. Strandberg TE, Vanhanen H, Tikkanen MJ: Effect of statins on c-reactive protein in patients with coronary artery disease. Lancet 1999, 353:118-119.
34. Fuster V, Stein B, Ambrose JA, et al.: Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990, 82 (Suppl 3):1147-1159.
35. Libby P: Molecular basis of acute coronary syndromes. Circulation 1995, 91:2844-2850.
36. Davies MJ: Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White lecture 1995. Circulation 1996, 94:2013-2020.
37. Lee RT, Libby P: The unstable atheroma. Arterioscler Thromb Vasc Biol 1997, 17:1859-1867.
38. Farb A, Burke AP, Tang AL, et al.: Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996, 93:1354-1363.
39. Bräsen JH, Harsch M, Niendorf A: Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet. Virchows Arch 1998, 432:557-562.
40. Bellosta S, Via D, Canavesi M, et al.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Aterioscler Thromb Vasc Biol 1998, 18:1671-1678.
41. Geng Y, Henderson LE, Levesque EB, et al.: Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17:2200-2208.
42. Negre-Aminoux P, van Vliet AK, van Erck M, et al.: Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors, comparison with other human cell types. Biochim Biophys Acta 1997, 1345:259-268.
43. Negata S, Goldstein P: The Fas death factor. Science 1995:1449-1456.
44. Knapp AC, Huang J, Starling G, et al.: Lipohilic statins sensitize human smooth muscle cells to Fas-mediated cell death. 70th EAS Congress, Geneva, Switzerland, September 6-9, 1998:101.
45. Kim Y, Bombeck A, Billiar TR: Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 1999, 84:253-256.
46. Nemerson Y: Tissue factor and haemostasis. Blood 1988, 71:1-8.
47. Colli S, Eligini S, Lalli M, et al.: Vastatins inhibit tissue factor in cultured human macrophages. Arterioscler Thromb Vasc Biol 1997, 17:265-272.
48. Broze GJ Jr.: The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992, 29:159-169.
49. Sanders NL, Bajaj SP, Zivelin A, et al.: Inhibition of tissue factor/factor VII activity in plasma requires factor X and an additional plasma component. Blood 1985, 66:204-212.
50. Carvalho AC, Colman RW, Less RS: Platelet function in hyperlipoproteinemia. N Engl J Med 1974, 290:434-438.
51. Corash L, Andersen J, Poindexter BJ, et al.: Platelet function and survival in patients with severe hypercholesterolemia. Arteriosclerosis 1981, 1:443-448.
52. Di Minno G, Silver MJ, Cerbone AM, et al.: Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis 1986, 6:203-211.
53. Nofer JR, Tepel M, Kehrel B, et al.: Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation 1997, 95:1370-1377.
54. Lacoste L, Lam JYT, Hung J, et al.: Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995, 92:3172-3177.
55. Xiang J, Lam JYT: Is inhibition of platelet thrombosis with pravastatin related to cholesterol reduction [abstract]? Circulation 1998, 98:I-250-I-251.
56. Lacoste L, Lam JYT: Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients [abstract]. J Am Col Cardiol 1996, 27:413A.
57. Rosenson RS: Viscosity and ischemic heart disease. J Vasc Med Biol 1993, 4:206-212.
58. Rumley A, Lowe GDO, Norrie J, et al., for the West of Scotland Coronary Prevention Study Group: Blood rheology and outcome in one West of Scotland Coronary Prevention Study: is the benefit of lipoprotein reduction partly due to lower viscosity? Br J Haematol 1997, 97(Suppl 1):78.
59. Lowe GDO, Lee AJ, Rumley A, et al.: Blood viscosity and the risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997, 96:168-171.
60. Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Annals Intern Med 1993, 118:956-963.
61. Heinrich JJ, Balleisen L, Schulte H, et al.: Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994, 14:54-59
62. Thompson SG, Kienast J, Pyke SDM, et al., for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995, 332:635-641.
63. Rosenson RS, Tangney CC: Beneficial effects of statins. Lancet 1996, 348:1583.
64. Baller D, Notochampiprodjo G, Gleichmann U, et al.: Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999, 99:2871-2875.
65. Davidson M, McKenney J, Stein E, et al.: Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997, 79:1475-1481.
66. Wierzbicki AS, Lumb PJ, Semra YK, et al.: Effect of atorvastatin on plasma fibrinogen. Lancet 1998, 351:569-570.
67. Isaacsohn J, Setaro JF, Nicholas C, et al.: Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994, 74:735-737.
68. Avellone G, Di Garbo V, Cordova R, et al.: Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr Ther Res Clin Exp 1994, 55:1335-1344.
69. Wada H, Mori Y, Kaneko T, et al.: Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992, 14:829-834.
70. Mitropoulos KA, Armitage JM, Collins R, et al.: Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. Eur Heart J 1997, 18:235-241.